Almirall Tidigare resultatutveckling
Tidigare kriterier kontrolleras 5/6
Almirall har ökat intäkterna med en genomsnittlig årlig takt på 22.8%, medan Pharmaceuticals -branschen såg intäkterna växer på 4.9% årligen. Intäkterna har varit växande med en genomsnittlig takt på 6.8% per år. Almirall s avkastning på eget kapital är 2.6% och den har en nettomarginal på 3.6%.
Viktig information
22.81%
Tillväxttakt i vinsten
13.93%
Tillväxttakt för EPS
| Pharmaceuticals Tillväxt i branschen | 4.99% |
| Intäkternas tillväxttakt | 6.79% |
| Avkastning på eget kapital | 2.64% |
| Nettomarginal | 3.56% |
| Nästa resultatuppdatering | 24 Jul 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Uppdatering av berättelse • Feb 03
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have nudged their price target on Almirall higher to €13.91 from €13.69, reflecting updated assumptions on revenue growth, profit margins and future P/E, despite a recent downgrade in stance from BNP Paribas. Analyst Commentary Analysts are sending mixed signals on Almirall, with a higher price target sitting alongside a more cautious rating.Uppdatering av berättelse • Jan 19
ALM: Future Re-Rating Will Rely On Dermatology Pipeline And Execution
Analysts slightly trimmed their price target for Almirall to €13.69 from €13.86, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Almirall plans to start a phase III study in the first half of 2026 evaluating Lebrikizumab (Ebglyss) for nummular eczema.Uppdatering av berättelse • Jan 05
ALM: Future Re-Rating Will Depend On Pipeline Execution And Ebglyss Ramp-Up
Narrative update on Almirall Analysts have raised their price target on Almirall to €14.50, citing what they see as a still-compelling valuation, along with expectations for Ebglyss ramp-up, upcoming clinical readouts, and potential in-licensing and M&A to support the mid-stage pipeline. Analyst Commentary Recent research points to a target price of €14.50 for Almirall, with the view that the shares still offer a compelling entry point despite a prior rebound in the stock.Uppdatering av berättelse • Dec 17
ALM: Future Re-Rating Will Hinge On Ebglyss Uptake And Pipeline Delivery
Analysts have modestly raised their price target on Almirall to EUR 14.50, citing expectations for a continued valuation re-rating supported by the ramp up of Ebglyss, upcoming clinical readouts, and potential in-licensing and M&A to bolster the mid-stage pipeline. Analyst Commentary Analyst views on Almirall remain broadly positive, with recent coverage highlighting both upside drivers and execution risks as the company advances its dermatology portfolio.Analysartikel • Dec 08
Market Cool On Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 2.6x is worth a...Uppdatering av berättelse • Dec 03
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have modestly raised their 12 month price target for Almirall to EUR 14.50, citing expectations that a continued re rating driven by Ebglyss ramp up, upcoming clinical readouts, and potential in licensing and M&A could support upside from current levels. Analyst Commentary Analysts note that Almirall's investment case is increasingly driven by visible growth levers in medical dermatology, but also caution that execution on product ramps and pipeline milestones will be critical to sustaining the recent share price rebound.Uppdatering av berättelse • Nov 19
ALM: Pipeline Milestones And Product Launch Momentum Will Drive Re-Rating
Analysts have increased their price target for Almirall from €13.30 to €13.87. They cite a compelling valuation, strong pipeline prospects, and expectations for continued growth driven by product launches and strategic developments.Analysartikel • Nov 17
Almirall's (BME:ALM) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Almirall, S.A.'s ( BME:ALM ) stock...Analysartikel • Nov 13
Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a good week for Almirall, S.A. ( BME:ALM ) shareholders, because the company has just released its latest...Analysartikel • Aug 19
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Jul 29
The Almirall, S.A. (BME:ALM) Interim Results Are Out And Analysts Have Published New Forecasts
Almirall, S.A. ( BME:ALM ) came out with its interim results last week, and we wanted to see how the business is...Ny berättelse • Jul 22
European Demographics Will Drive Advancements In Dermatology Treatments
Strong specialty product launches and robust R&D pipeline are expected to drive growth, improve margins, and boost Almirall's market position in innovative dermatology.Analysartikel • May 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 44% Above Its Share Price
Key Insights The projected fair value for Almirall is €14.08 based on 2 Stage Free Cash Flow to Equity Current share...Analysartikel • Mar 27
Why We're Not Concerned About Almirall, S.A.'s (BME:ALM) Share Price
With a median price-to-sales (or "P/S") ratio of close to 2.2x in the Pharmaceuticals industry in Spain, you could be...Analysartikel • Mar 03
Statutory Profit Doesn't Reflect How Good Almirall's (BME:ALM) Earnings Are
Almirall, S.A. ( BME:ALM ) recently posted some strong earnings, and the market responded positively. Our analysis...Analysartikel • Feb 12
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Dec 10
Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Analysartikel • Nov 14
Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Almirall, S.A. ( BME:ALM ) shareholders are probably feeling a little disappointed, since its shares fell 2.9% to €8.52...Analysartikel • Nov 06
Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Sep 07
Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)
You may think that with a price-to-sales (or "P/S") ratio of 2x Almirall, S.A. ( BME:ALM ) is a stock worth checking...Analysartikel • Jul 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Almirall fair value estimate is €18.31 Current share price of...Analysartikel • Apr 24
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Analysartikel • Mar 20
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Dec 15
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysartikel • Oct 03
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?
Key Insights Almirall's estimated fair value is €11.86 based on 2 Stage Free Cash Flow to Equity Almirall's €9.37 share...Analysartikel • Aug 24
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Jul 05
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 31% Undervaluation?
Key Insights Almirall's estimated fair value is €11.37 based on 2 Stage Free Cash Flow to Equity Current share price of...Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur Almirall tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 1,121 | 40 | 263 | -1 |
| 31 Dec 25 | 1,115 | 46 | 264 | 0 |
| 30 Sep 25 | 1,085 | 42 | 256 | 12 |
| 30 Jun 25 | 1,054 | 21 | 249 | 0 |
| 31 Mar 25 | 1,028 | 24 | 246 | 9 |
| 31 Dec 24 | 991 | 10 | 235 | 0 |
| 30 Sep 24 | 953 | -45 | 237 | 12 |
| 30 Jun 24 | 932 | -35 | 220 | 0 |
| 31 Mar 24 | 915 | -39 | 214 | 3 |
| 31 Dec 23 | 899 | -38 | 209 | 0 |
| 30 Sep 23 | 907 | 7 | 209 | 7 |
| 30 Jun 23 | 898 | -11 | 201 | 0 |
| 31 Mar 23 | 882 | -8 | 205 | 3 |
| 31 Dec 22 | 879 | 4 | 202 | 0 |
| 30 Sep 22 | 864 | 9 | 207 | 24 |
| 30 Jun 22 | 856 | 29 | 197 | 0 |
| 31 Mar 22 | 843 | -50 | 190 | 8 |
| 31 Dec 21 | 837 | -41 | 188 | 0 |
| 30 Sep 21 | 814 | -22 | 201 | -10 |
| 30 Jun 21 | 809 | -11 | 185 | 0 |
| 31 Mar 21 | 790 | 55 | 188 | -8 |
| 31 Dec 20 | 814 | 74 | 177 | 0 |
| 30 Sep 20 | 849 | 63 | 167 | -8 |
| 30 Jun 20 | 872 | 86 | 188 | 0 |
| 31 Mar 20 | 926 | 121 | 188 | 0 |
| 31 Dec 19 | 911 | 106 | 189 | 0 |
| 30 Sep 19 | 858 | 85 | 227 | 9 |
| 30 Jun 19 | 884 | 88 | 182 | 0 |
| 31 Mar 19 | 789 | 80 | 209 | 3 |
| 31 Dec 18 | 811 | 78 | 183 | 0 |
| 30 Sep 18 | 714 | -111 | 176 | -10 |
| 30 Jun 18 | 730 | -179 | 196 | 0 |
| 31 Mar 18 | 687 | -293 | 195 | -6 |
| 31 Dec 17 | 677 | -304 | 207 | 0 |
| 30 Sep 17 | 735 | -128 | 215 | 5 |
| 30 Jun 17 | 755 | -78 | 214 | 0 |
| 31 Mar 17 | 821 | 73 | 216 | 5 |
| 31 Dec 16 | 822 | 75 | 213 | 0 |
| 30 Sep 16 | 778 | 162 | 230 | 10 |
| 30 Jun 16 | 743 | 154 | 210 | 0 |
| 31 Mar 16 | 721 | 111 | 204 | 2 |
| 31 Dec 15 | 738 | 132 | 201 | 0 |
| 30 Sep 15 | 783 | 479 | 190 | -28 |
| 30 Jun 15 | 802 | 488 | 244 | 0 |
Kvalitetsintäkter: ALM har inkomster av hög kvalitet.
Växande vinstmarginal: ALM s nuvarande netto vinstmarginaler (3.6%) är högre än förra året (2.4%).
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: ALM s intäkter har ökat markant med 22.8% per år under de senaste 5 åren.
Accelererande tillväxt: ALM s intäktstillväxt under det senaste året ( 63.7% ) överstiger sitt 5-åriga genomsnitt ( 22.8% per år).
Resultat vs industri: ALM vinsttillväxt under det senaste året ( 63.7% ) översteg Pharmaceuticals branschen 15.3%.
Avkastning på eget kapital
Hög ROE: ALM s avkastning på eget kapital ( 2.6% ) anses vara låg.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/10 02:37 |
| Aktiekurs vid dagens slut | 2026/06/10 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Almirall, S.A. bevakas av 27 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |